Search

Your search keyword '"C. Kerkhof"' showing total 4 results
Start Over Author "C. Kerkhof" Publication Year Range Last 10 years
4 results on '"C. Kerkhof"'

1. The association between viral load and concurrent human papillomavirus infection at the genital and anal sites of young women and the impact of vaccination

Author

Kahren van Eer, Ihsane Laâbi, Birgit H.B. van Benthem, Renske D.M. Steenbergen, Audrey J. King, D. Adema, R. Buist-Arkema, A. Beerens, D. Luijt, S. Meijer, J. Schirm, M. Peeters, J. Rossen, H. Verbakel, P. van Esch, J. Verweij, A. van der Eijk, R. Huisman, C. Kerkhof, H. Korff, M. Schutten, J. Velzing, F. Verduyn-Lunel, S. Lakbiach, P. van Rosmalen, R. Schuurman, E. Doorn, L. Masthoff, E. Pannekoek, V. Sigurdsson, D. Abma, K. Adams, S. Bruisten, I. Linde, P. Oostvogel, C. Touwen, W. Vermeulen, A. Brink, J. Nelissen, P. Wolffs, N. Duijvendijk, P. Schneeberger, M. Dinnissen van Poppel, W. Melchers, Y. Poort, M.Hooghiemstra Izore, H. Huisman, J. Weel, F. Bosma, F. Geeraedts, I. Polman, P.van Goor Isala, M. Wolfhagen, C. de Mooij, E. van Koolwijk, M. Peters, C. Swanink, R. Tiemessen, T. van Zwet, J. Janssen, M. Pelsers, W. de Waal, G. Aalfs, J. Kiewiet, P. Sanders, H. van Buel- Bruins, C. van Bokhoven-Rombouts, P. Cornelissen, M. Kersten, C. van Ruitenbeek, I. Molenaar, M. Bugter, H. Götz, M. Illidge-Onder de Linden, M. Mattijssen, J. Stam, E. Swaders, F. de Groot, F. Postma, E. Brouwers, A. Niekamp, M. Smit, A. Botraby, D. Bukasa, C. de Haan, P. Hut-van Vliet, T. Taconis, M. de Graas, I. Hondelink, C. Kampman, A. Gelissen-Hansen, I. de Koning, H. van Kruchten, M. van de Pas, H. Fennema, T. Heijman, A. Hogewoning, A. van Leeuwen, M. van Rooijen, F. Neienhuijsen, and M. Pelgrim

Subjects
Human papillomavirus, Concurrent, Viral load, Vaccination, Genital, Anal, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Concurrent genital-anal human papillomavirus (HPV) infections may impose an increased anal cancer risk in women with HPV-related genital lesions. High viral load may facilitate genital-anal HPV concurrence. Genital and anal HPV is reduced by a bivalent HPV16/18 vaccine, yet the effect on concurrent genital-anal HPV remains unclear.This study analyzed viral load in concurrent genital-anal HPV infections, relative to genital-only and anal-only HPV infections and the impact of vaccination in young women. We included 1074 women, who provided both genital and anal swabs. HPV detection and genotyping was performed using the SPF10-DEIA-LiPA25. HPV copy numbers were measured with type-specific qPCRs and corrected for cellular content to obtain the viral load.Concurrent genital-anal HPV often had significantly higher genital viral load (0.09–371 c/cell) than genital-only HPV (3.17E-04-15.9 c/cell, p

Published
2022
Full Text
View/download PDF

2. Therapeutic Strategies for Spinocerebellar Ataxia Type 1

Author

Laurie M. C. Kerkhof, Bart P. C. van de Warrenburg, Willeke M. C. van Roon-Mom, and Ronald A. M. Buijsen

Subjects
Spinocerebellar ataxia type 1, neurodegenerative disorder, therapeutic strategies, preclinical research, clinical trials, gain-of-function mechanism, Microbiology, QR1-502
Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder that affects one or two individuals per 100,000. The disease is caused by an extended CAG repeat in exon 8 of the ATXN1 gene and is characterized mostly by a profound loss of cerebellar Purkinje cells, leading to disturbances in coordination, balance, and gait. At present, no curative treatment is available for SCA1. However, increasing knowledge on the cellular and molecular mechanisms of SCA1 has led the way towards several therapeutic strategies that can potentially slow disease progression. SCA1 therapeutics can be classified as genetic, pharmacological, and cell replacement therapies. These different therapeutic strategies target either the (mutant) ATXN1 RNA or the ataxin-1 protein, pathways that play an important role in downstream SCA1 disease mechanisms or which help restore cells that are lost due to SCA1 pathology. In this review, we will provide a summary of the different therapeutic strategies that are currently being investigated for SCA1.

Published
2023
Full Text
View/download PDF

3. Feasibility and impact of a dedicated multidisciplinary rehabilitation program on health-related quality of life in advanced head and neck cancer patients

Author

Frans J. M. Hilgers, Martijn M. Stuiver, Ellen Passchier, Lisette van der Molen, Stefanie I. C. Kerkhof, Michiel W. M. van den Brekel, MKA AMC (OII, ACTA), ACLC (FGw), Epidemiology and Data Science, Master Evidence Based Practice, Oral and Maxillofacial Surgery, Other departments, and Maxillofacial Surgery (AMC)

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Population, Psychological intervention, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Surveys and Questionnaires, medicine, Humans, Prospective Studies, 030223 otorhinolaryngology, education, Prospective cohort study, Aged, education.field_of_study, Rehabilitation, business.industry, Head and neck cancer, General Medicine, Middle Aged, medicine.disease, humanities, Distress, Otorhinolaryngology, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Quality of Life, Physical therapy, Feasibility Studies, Female, Observational study, Symptom Assessment, business, Stress, Psychological, Program Evaluation
Abstract

In an observational prospective study, feasibility and outcomes of a dedicated multidisciplinary rehabilitation program (HNR) for head and neck cancer (HNC) patients were evaluated. HRQoL was assessed before and after HNR with EORTC C30 and H&N-35 QoL questionnaires in 52 consecutive patients. Initial HRQoL scores were compared with EORTC reference scores for HNC patients and post-HNR with those available for the general healthy population. Distress was assessed before and after HNR with the distress thermometer (DT). At completion of HNR with a mean duration of 7 months, overall HRQoL was significantly improved (p < 0.001). Role, Emotional, and Social function scales and most EORTC C30 and H&N35 symptom scale items showed a statistically significant (p < 0.01) and clinically relevant improvement. Mean distress score before HNR was above the cutoff value of 5, suggesting the need for referral to rehabilitation. After completing HNR, distress decreased significantly to 3.0 (p < 0.001). HRQoL pretreatment was poorer than that of the EORTC reference HNC population, whereas at the completion of the HNR program, the HRQoL was comparable to that of the general population reference level. We conclude that a dedicated multidisciplinary HNR program is feasible and suggest that it has a positive impact on HRQoL. The multidisciplinary approach may have added value over mono-disciplinary interventions. However, our results should be judged cautiously due to the observational nature of the study.

Published
2016
Full Text
View/download PDF

4. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Author

J. Weel, P. Oostvogel, I. Molenaar, Audrey J. King, J. Schirm, E. Doorn, Petra F. G. Wolffs, Christian J. P. A. Hoebe, M. van de Pas, I. de Koning, J. Janssen, A. Gelissen-Hansen, M. Illidge-Onder de Linden, P. Sanders, M. Hooghiemstra, J. Kiewiet, Han S. A. Fennema, C. de Mooij, P. Hut-van Vliet, S. Lakbiach, Dirk S. Luijt, M. Pelsers, F. De Groot, T. van Zwet, M. Wolfhagen, H. Huisman, C. van Ruitenbeek, L. Masthoff, C. Touwen, H. Verbakel, Antoinette A. T. P. Brink, M. Schutten, K. Adams, I. Hondelink, N. Duijvendijk, R. Tiemessen, A.G.M. Buiting, Arjan Hogewoning, Robine Donken, Antoine M Beerens, T. de Haas, F. Postma, M. de Graas, F. Verduyn-Lunel, Jaco J. Verweij, Peter M. Schneeberger, T. Taconis, Titia Heijman, V. Sigurdsson, D. Adema, Elfi E. H. G. Brouwers, Petra J. Woestenberg, Menke J. de Smit, Johannes A. Bogaards, E. Pannekoek, E. van Koolwijk, I. Linde, P. Cornelissen, W. Vermeulen, C. van Bokhoven-Rombouts, Sylvia M. Bruisten, A. van Leeuwen, W. de Waal, R. Huisman, Marianne A B van der Sande, G. Aalfs, A. Botraby, Marcel Peeters, Hannelore M Götz, D. Abma, A.A. van der Eijk, R. Buist-Arkema, H. Korff, H. Bosch, C. de Haan, M. van Rooijen, H. van Buel-Bruins, S. Meijer, P. van Goor, E. Swaders, Fiona R. M. van der Klis, P. van Esch, M. Mattijssen, I. Polman, Birgit H B van Benthem, M. Dinnissen-van Poppel, J. Stam, John W. A. Rossen, Caroline M. A. Swanink, Rob Schuurman, T. Smits, J. Nelissen, C. Kampman, M. Peters, Willem J. G. Melchers, M. Pelgrim, C. Kerkhof, J. Velzing, Suzan Leussink, H. van Kruchten, D. Bukasa, P. van Rosmalen, Y. Poort, F. Neienhuijsen, M. Kersten, Anne-Marie Niekamp, R. Kleinspenkelink, CCA - Cancer biology and immunology, AII - Infectious diseases, Pathology, APH - Methodology, Other departments, APH - Global Health, Medical Microbiology and Infection Prevention, Neurology, Promovendi PHPC, Med Microbiol, Infect Dis & Infect Prev, and RS: CAPHRI - R4 - Health Inequities and Societal Participation

Subjects
0301 basic medicine, Cross-sectional study, Cross Protection, NETHERLANDS, Uterine Cervical Neoplasms, PAPILLOMAVIRUS, Ambulatory Care Facilities, Genital warts, GENITAL WARTS, 0302 clinical medicine, Prevalence, 030212 general & internal medicine, Cervical cancer, Human papillomavirus 16, Human papillomavirus 18, Human papillomavirus 11, Prevention & control, Vaccination, WOMEN, virus diseases, medicine.anatomical_structure, Infectious Diseases, ANOGENITAL WARTS, Vagina, Female, Warts, Adult, Microbiology (medical), medicine.medical_specialty, CERVICAL-CANCER, Adolescent, 030106 microbiology, Sexually Transmitted Diseases, Human papillomavirus vaccine, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Journal Article, Humans, Sex organ, Papillomavirus Vaccines, Human papillomavirus vaccine, L1 type 16, 18, Gynecology, Condylomata acuminata, business.industry, RISK HPV TYPES, Papillomavirus Infections, Vaccine trial, AS04-ADJUVANTED VACCINE, medicine.disease, Human papillomavirus 6, EFFICACY, Confidence interval, United Kingdom, Cross-Sectional Studies, INTRAEPITHELIAL NEOPLASIA, L1 type 16, business
Abstract

Objectives: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.Results: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results.Conclusions: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW. (C) 2017 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results